Home
Live Updates
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer : comparemela.com
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.
Related Keywords
Barcelona ,
Comunidad Autonoma De Cataluna ,
Spain ,
Hebron ,
Israel General ,
Israel ,
Daiichi Sankyo Astrazeneca ,
Mafalda Oliveira ,
Pfizer ,
Genentech ,
Breast Cancer Congress ,
Novartis ,
Astrazeneca ,
Hebron University Hospital ,
Breast Cancer Group ,
Hebron Institute Of Oncology ,
Oncology Department Of The Breast Cancer Group ,
Ayala Pharmaceuticals ,
Medical Oncology Department ,
University Hospital ,
Hebron Institute ,
Zenith Epigenetics ,
Cureos Science ,
Relay Therapeutics ,
comparemela.com © 2020. All Rights Reserved.